Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19054180 | GLP-1R AGONIST COMPOUND AND USE THEREOF | February 2025 | June 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18980700 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | December 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18951509 | PLEUROMUTILIN ONIUM SALT DERIVATIVE CONTAINING A 3H-IMIDAZO[4,5-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOF | November 2024 | January 2025 | Allow | 2 | 1 | 0 | No | No |
| 18854563 | RUTHENIUM PRECURSOR COMPOSITION, PREPARATION METHOD THEREFOR, AND FORMATION METHOD FOR RUTHENIUM-CONTAINING FILM USING SAME | October 2024 | February 2025 | Allow | 4 | 0 | 0 | No | No |
| 18762532 | HETEROCYCLIC GLP-1 AGONISTS | July 2024 | August 2024 | Allow | 2 | 0 | 0 | No | No |
| 18669184 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | May 2024 | June 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18644945 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | April 2024 | May 2025 | Allow | 13 | 0 | 0 | No | No |
| 18635402 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18617266 | APOL1 INHIBITORS AND METHODS OF USE | March 2024 | February 2025 | Allow | 11 | 1 | 0 | No | No |
| 18604314 | THERAPEUTIC COMPOUNDS | March 2024 | May 2025 | Allow | 14 | 1 | 1 | Yes | No |
| 18443447 | METHODS AND COMPOSITIONS FOR MAINTAINING OPIOID EFFICACY IN THE TREATMENT OF PAIN | February 2024 | April 2025 | Allow | 14 | 2 | 0 | Yes | No |
| 18442788 | PYRROLO[2,3-C][2,6]NAPHTHYRIDINE-8-CARBOXYLIC ACIDS AS CK2 INHIBITORS | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18435998 | PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USE | February 2024 | February 2025 | Allow | 12 | 1 | 0 | No | No |
| 18434637 | IMIDAZO[1,5-a]PYRIDO[4,3-e]PYRAZINES AS CK2 INHIBITORS | February 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18433717 | COMPOUNDS, COMPOSITIONS AND METHODS | February 2024 | December 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18414429 | PYRAZOLO[4,3-C][2,6]NAPHTHYRIDINES AS CK2 INHIBITORS | January 2024 | April 2024 | Allow | 3 | 1 | 0 | No | No |
| 18409989 | PYRIDO[4,3-e]PYRROLO[1,2-a]PYRIMIDINE AS CK2 INHIBITORS | January 2024 | April 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18407001 | IMIDAZO[1,2-C]PYRIDO[3,4-E]PYRIMIDINE-3-CARBOXYLIC ACIDS AS CK2 INHIBITORS | January 2024 | March 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18396198 | 2-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-3-OL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | December 2023 | February 2024 | Allow | 2 | 0 | 0 | No | No |
| 18394421 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | December 2023 | August 2024 | Allow | 7 | 0 | 0 | No | No |
| 18392204 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | December 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18391039 | PYRAZOLO[4,3-C][1,6]NAPHTHYRIDINES AS CK2 INHIBITORS | December 2023 | February 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18543151 | Functionalized Heterocycles as Antiviral Agents | December 2023 | October 2024 | Allow | 10 | 1 | 0 | No | No |
| 18543599 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | December 2023 | May 2024 | Allow | 5 | 1 | 0 | No | No |
| 18543272 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | December 2023 | November 2024 | Allow | 10 | 1 | 0 | No | No |
| 18535055 | BLUE PHOSPHORESCENT EMITTERS EMPLOYING FUNCTIONALIZED IMIDAZOPHENTHRIDINE AND ANALOGUES | December 2023 | June 2025 | Allow | 18 | 2 | 1 | No | No |
| 18515743 | TREATING PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY | November 2023 | January 2025 | Allow | 14 | 2 | 0 | No | No |
| 18512473 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | November 2023 | January 2025 | Allow | 14 | 3 | 0 | No | Yes |
| 18511344 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18510120 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | November 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18386231 | MULTI-TARGET DRUG CANDIDATES FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | November 2023 | March 2024 | Allow | 4 | 1 | 1 | No | No |
| 18386198 | MULTI-TARGET DRUG CANDIDATES FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18386139 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | November 2023 | April 2025 | Allow | 17 | 1 | 1 | No | No |
| 18494550 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | October 2023 | July 2024 | Allow | 9 | 2 | 0 | No | No |
| 18493667 | CRYSTALLINE FORMS OF CFTR MODULATORS | October 2023 | January 2025 | Allow | 15 | 0 | 0 | No | No |
| 18484259 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | October 2023 | June 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18377633 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | October 2023 | May 2025 | Allow | 20 | 1 | 0 | No | No |
| 18376525 | SMALL MOLECULE INHIBITORS TARGETING CLOSTRIDIOIDES DIFFICILE SPORULATION | October 2023 | July 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18475489 | Crystal and Amorphous Form of Tolebrutinib, Preparation Method Therefor, and Use Thereof | September 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18370742 | 7-(4-((4-BENZYLIDENE-5-OXO-2-PHENYL-4,5-DIHYDRO-1H-IMIDAZOL-1-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUND | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18369537 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | September 2023 | July 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18369071 | METHODS OF TREATING NEUROEPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | September 2023 | January 2025 | Allow | 16 | 1 | 0 | No | No |
| 18241427 | 7-(4-((5-(3-BROMOBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | September 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18239842 | COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES | August 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18240012 | 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE | August 2023 | January 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18237535 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | August 2023 | August 2024 | Allow | 12 | 1 | 0 | No | No |
| 18237273 | ETHYL 2-SUBSTITUTED-1-(SUBSTITUTEDBENZOYL)-7-METHYLPYRROLO[1,2-a]QUINOLINE-3-CARBOXYLATE DERIVATIVES AS ANTI-TUBERCULAR AGENTS | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18230585 | ADENOSINE RECEPTOR ACTIVITY OF METHYL/ETHYL 3-(SUBSTITUTED BENZOYL)-6,8-DIMETHYLINDOLIZINE-2-SUBSTITUTED-1-CARBOXYLATES | August 2023 | March 2024 | Allow | 7 | 3 | 0 | Yes | No |
| 18272252 | KIFUNENSINE DERIVATIVES | July 2023 | February 2024 | Allow | 7 | 1 | 0 | No | No |
| 18220484 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | July 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18349336 | Arginase Inhibitors and Methods of Use Thereof | July 2023 | November 2023 | Allow | 4 | 1 | 0 | No | No |
| 18217084 | MULTI-TARGET DRUG CANDIDATES FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER | June 2023 | October 2023 | Allow | 3 | 0 | 1 | Yes | No |
| 18217009 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | June 2023 | September 2023 | Allow | 3 | 1 | 0 | No | No |
| 18217037 | TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOF | June 2023 | September 2023 | Allow | 15 | 1 | 0 | No | No |
| 16767155 | NORADRENERGIC AND SPECIFIC SEROTONERGIC ANXIOLYTIC AND ANTIDEPRESSANT, METHOD FOR THE PRODUCTION AND USE THEREOF | June 2023 | November 2024 | Allow | 54 | 2 | 0 | No | No |
| 18330932 | PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE | June 2023 | November 2023 | Allow | 5 | 2 | 1 | Yes | No |
| 18205877 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | June 2023 | June 2024 | Allow | 12 | 0 | 0 | No | No |
| 18319585 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | May 2023 | August 2024 | Allow | 15 | 1 | 1 | No | No |
| 18319287 | SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF | May 2023 | May 2025 | Allow | 24 | 1 | 0 | No | No |
| 18143781 | MULTIVARIATE METAL-ORGANIC FRAMEWORKS FOR FINE-TUNING LIGHT EMISSION | May 2023 | November 2024 | Allow | 18 | 1 | 1 | No | No |
| 18142263 | PSILOCIN PRODRUG COMPOUNDS AND METHODS OF SYNTHESIZING THE SAME | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18138817 | COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES | April 2023 | July 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18306710 | MORPHINAN COMPOUNDS | April 2023 | January 2025 | Allow | 21 | 1 | 0 | No | No |
| 18302995 | Tetradentate Metal Complexes with Carbon Group Bridging Ligands | April 2023 | December 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18132777 | Pan-Tropic Entry Inhibitors | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18296543 | NOVEL DIZOCILPINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18194678 | METHOD OF CONTROLLING DEPRESSION IN SUBJECTS TREATED FOR OPIOID DEPENDENCE | April 2023 | October 2024 | Allow | 18 | 1 | 0 | No | No |
| 18187430 | EGFR INHIBITORS | March 2023 | October 2024 | Allow | 19 | 1 | 0 | No | No |
| 18182287 | BODIPY-BASED RHOMBIC METAL RING, PREPARATION METHOD THEREOF, AND APPLICATION IN NEAR-INFRARED REGION IMAGING | March 2023 | May 2023 | Allow | 2 | 0 | 0 | No | No |
| 18025017 | GROUP 4 METAL ELEMENT-CONTAINING COMPOUND, PRECURSOR COMPOSITION INCLUDING SAME, AND METHOD FOR MANUFACTURING THIN FILM USING SAME | March 2023 | March 2025 | Allow | 24 | 1 | 1 | No | No |
| 18111421 | Methods for Treating Huntington's Disease | February 2023 | October 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18110126 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | February 2023 | April 2024 | Allow | 14 | 0 | 0 | No | No |
| 18169660 | NONMUSCLE MYOSIN II INHIBITORS | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18166346 | QUINOLINE-2,3-FUSED NINE-MEMBERED RING SCAFFOLD COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF AS EFFECTIVE COMPONENT IN PLANT FUNGICIDE | February 2023 | September 2023 | Allow | 7 | 2 | 0 | No | No |
| 18103662 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL DISEASE | January 2023 | July 2024 | Allow | 18 | 1 | 0 | No | No |
| 18103173 | LIQUID PHARMACEUTICAL FORMULATIONS OF APIXABAN | January 2023 | July 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18100992 | SPIROCYCLIC COMPOUNDS | January 2023 | September 2024 | Allow | 20 | 1 | 1 | No | No |
| 18098070 | APOL1 INHIBITORS AND METHODS OF USE | January 2023 | November 2023 | Allow | 10 | 1 | 0 | No | No |
| 18096996 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | January 2023 | August 2023 | Allow | 8 | 1 | 1 | No | No |
| 18068951 | IRAK DEGRADERS AND USES THEREOF | December 2022 | January 2025 | Allow | 25 | 1 | 0 | No | No |
| 18067384 | HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS | December 2022 | October 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18064952 | Pt-xanthene-iodine complex and Pt-xanthene-bromine complex | December 2022 | October 2023 | Allow | 10 | 2 | 0 | No | No |
| 18065219 | SMAD4 Complex Inducers and Uses in Cancer Therapy | December 2022 | June 2024 | Abandon | 18 | 2 | 0 | Yes | No |
| 18060456 | MASP-2 INHIBITORS AND METHODS OF USE | November 2022 | August 2024 | Allow | 21 | 1 | 1 | No | No |
| 18060098 | FASORACETAM CRYSTALLINE FORMS | November 2022 | May 2024 | Allow | 18 | 1 | 0 | No | No |
| 17927324 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | November 2022 | February 2024 | Allow | 15 | 0 | 0 | No | No |
| 17990133 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 17918135 | TRICYCLIC PESTICIDAL COMPOUNDS | October 2022 | June 2025 | Allow | 32 | 0 | 0 | No | No |
| 17962187 | HALOGENATED DERIVATIVES OF MORPHINANS AND USES THEREOF | October 2022 | December 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17962346 | DOPAMINE D2 RECEPTOR LIGANDS | October 2022 | May 2025 | Allow | 31 | 3 | 1 | Yes | No |
| 17961270 | ADDITION SALT OF S1P1 RECEPTOR AGONIST AND CRYSTAL FORM THEREOF, AND PHARMACEUTICAL COMPOSITION | October 2022 | September 2024 | Allow | 23 | 1 | 0 | No | No |
| 17957103 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | September 2022 | June 2024 | Allow | 20 | 1 | 0 | No | No |
| 17957350 | TREATMENT OF DEMYELINATING DISEASES | September 2022 | February 2025 | Allow | 28 | 2 | 0 | No | No |
| 17933213 | MONOCARBORANE CLUSTER -CONTAINING PLATINUM COMPLEXES AND PREPARATION METHOD AND OLED APPLICATION | September 2022 | August 2023 | Allow | 11 | 0 | 0 | No | No |
| 17932705 | TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES | September 2022 | October 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17946129 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | September 2022 | June 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17931801 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | September 2022 | November 2024 | Allow | 26 | 2 | 0 | No | No |
| 17944060 | TETRAHYDROISOQUINOLINE DERIVATIVES | September 2022 | March 2024 | Allow | 18 | 0 | 0 | No | No |
| 17942555 | MORPHINAN COMPOUNDS | September 2022 | July 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17823910 | CARDIAC SARCOMERE INHIBITORS | August 2022 | April 2024 | Allow | 19 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AULAKH, CHARANJIT.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 58.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner AULAKH, CHARANJIT works in Art Unit 1621 and has examined 1,092 patent applications in our dataset. With an allowance rate of 93.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 20 months.
Examiner AULAKH, CHARANJIT's allowance rate of 93.9% places them in the 82% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by AULAKH, CHARANJIT receive 1.20 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by AULAKH, CHARANJIT is 20 months. This places the examiner in the 87% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +1.3% benefit to allowance rate for applications examined by AULAKH, CHARANJIT. This interview benefit is in the 16% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 37.9% of applications are subsequently allowed. This success rate is in the 84% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 79.5% of cases where such amendments are filed. This entry rate is in the 95% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 142.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 87% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 98.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 51.2% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 17.1% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.